Skip to main content
Equibles

Jim Hollingshead

CEO

Insulet Corp (PODD)

Equibles does not estimate personal net worth.

Get an email with a short summary when Insulet Corp publishes a filing, an earnings call transcript or a press release.

Get PODD alerts

About Jim Hollingshead

Jim Hollingshead is recorded as CEO at Insulet Corp (PODD). Jim Hollingshead was last confirmed as Board Member at Resmed Inc (RMD) in a filing dated October 5, 2022. Insulet Corp reported in an 8-K filed April 28, 2025 that Jim Hollingshead resigned as Insulet Board of Directors, effective April 28, 2025. Jim Hollingshead has spoken on 9 earnings calls across 1 company, most recently for Insulet Corp on February 20, 2025. Insulet Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Insulet Corp includes Ashley A. McEvoy (CEO and Board Member), Ashley McEvoy (CEO and Board Member), Timothy J. Scannell (Chairman) and 7 others.

“Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors.”
Insulet Corp Form 8-K, filed April 28, 2025 · Read the filing

Jim Hollingshead on recent calls

“We concluded an incredible year with a very strong fourth quarter, achieving several milestones across the business, as well as every one of our growth and margin objectives.”
CEO, Insulet Corp Q4 FY2024 Earnings Call ·
“We delivered another strong quarter of financial results and achieved several outstanding milestones throughout our business. I am proud of what our team accomplishes every day to create better health outcomes for our customers, set new standards in the management of diabetes and drive success across our organization.”
CEO, Insulet Corp Q3 FY2024 Earnings Call ·
“2024 is shaping up to be another year of rapid growth, fueled by strong demand for Omnipod 5 and our accelerating pace of product innovation.”
CEO, Insulet Corp Q2 FY2024 Earnings Call ·
“With our strong Q4 2023 results, we capped off another transformational year, in which we firmly established Insulet as the market leader in automated insulin delivery.”
CEO, Insulet Corp Q4 FY2023 Earnings Call ·
“Q3 was another strong quarter for Insulet with rapid growth and achievement of many strategic milestones. Thanks to our global team's execution, dedication, and focus, we are on track to complete another transformational year and enter 2024 with significant momentum.”
CEO, Insulet Corp Q3 FY2023 Earnings Call ·

Affiliation history

Company network

Resmed Inc

RMD

Medical Instruments & Supplies · Healthcare

Board Member

Leadership on record at Insulet Corp

Recent activity